Pharmaceuticals

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of$50 million, with Lilly Asia Ventures (LAV) as lead ...

2021-08-27 08:00 6421

JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions

Population–based cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs. PLYMOUTH MEETING, Pa., Aug. 27, 2021 /PRNewswire/ -- Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer...

2021-08-27 03:30 2241

Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases

SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, and4B Technologies Co., Ltd. ("4B Technologies"), a leading end-to-end innovative biopharmaceutical company focusing on nervous system diseases, signed...

2021-08-27 03:22 32157

PharmaBlock Announces the Appointment of Dr. Xudong Wei as Senior Vice President to Lead and Enhance Small Molecule CDMO Services

NANJING, China, Aug. 26, 2021 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr.Xudong Wei as Senior Vice President and Head of CDMO Business to enhance s...

2021-08-26 23:00 4345

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...

2021-08-26 22:09 6862

Modern Chinese Medicine Announces Year 2021 Interim Results

PERFORMANCE HIGHLIGHTS * Revenue increased by 8.8% to RMB171.8 million * Gross profit increased by 10.4% to RMB78.6 million * Profit after tax increased by 10.5% to approximately RMB44.1 million * The increase in revenue was primarily driven by the surge in revenue generated from the sales...

2021-08-26 20:46 5806

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

INOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NAS...

2021-08-26 20:00 4060

RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter...

2021-08-26 19:56 7752

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibiti...

2021-08-26 19:50 4068

CStone Pharmaceuticals Announces 2021 Interim Results

SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced 2021 financial results. "In the first...

2021-08-26 19:14 6399

First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has ...

2021-08-25 21:18 6628

Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-08-25 20:53 5996

Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia

SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has entered into a licensing agreement with PT Etana Biotechnol...

2021-08-25 19:25 4940

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

TAIPEI and SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced the initiation of Dose Escalation within the Phase I Investigator Init...

2021-08-25 19:00 2183

Moolec Science and Grupo Insud Launch Food-Tech Joint Venture

WARWICK, England, Aug. 25, 2021 /PRNewswire/ -- Moolec, a science-based ingredients company using plants to produce animal proteins, andGrupo Insud, a global conglomerate with a strong presence in the manufacturing of biosimilars and other active ingredients for the pharmaceutical industry, annou...

2021-08-25 18:00 1908

Extended Malaysian wound care tender: Bactiguard Holding

STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Bactiguard's tender award for wound care products for the public sector inMalaysia has been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard's Wound Care syst...

2021-08-25 15:49 1987

Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength

HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two oph...

2021-08-25 12:35 4447

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical need and large public health...

2021-08-25 08:42 3916

Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication

HANGZHOU and SHAOXING, China, Aug. 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 inChina for chronic hepatitis B (CHB) indication. ASC42 is an in-house de...

2021-08-25 08:30 4667

GenScript Biotech Reports First Half 2021 Results

* In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million , achieving a 28.1% YoY growth. All four of the Group's business segments demonstrated steady growth. * Building on early strategic invest...

2021-08-24 21:38 6987
1 ... 331332333334335336337 ... 343